Loading clinical trials...
Loading clinical trials...
A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Escalating Subcutaneous Doses Of PF-04603629 In Type 2 Diabetic Adult Subjects
PF 04603629 is a long acting exendin proposed for the treatment of Type 2 diabetes mellitus. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics and glucose lowering capabilities following a single subcutaneous dose.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Start Date
August 1, 2007
Completion Date
February 1, 2008
Last Updated
July 31, 2009
71
ACTUAL participants
Placebo
BIOLOGICAL
PF-04603629
BIOLOGICAL
Lead Sponsor
Pfizer
NCT06959901
NCT06574035
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06861062